Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
Abstract Background The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first time that patients were completely free of viable tumor. Case presentation...
Main Authors: | Stefan Schliep, Abbas Agaimy, Alexander Cavallaro, Franklin Kiesewetter, Gerold Schuler, Lucie Heinzerling |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2018-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-017-0309-3 |
Similar Items
-
Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
by: Teresa Amaral, et al.
Published: (2020-04-01) -
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021-07-01) -
Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma
by: Dharmesh Gopalakrishnan, et al.
Published: (2021-04-01) -
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
by: Teresa Kim, et al.
Published: (2014-12-01) -
LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma
by: Sandra van Wilpe, et al.
Published: (2021-04-01)